These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
152 related articles for article (PubMed ID: 9369265)
1. Effects of SR 49059, a new orally active and specific vasopressin V1 receptor antagonist, on vasopressin-induced vasoconstriction in humans. Weber R; Pechère-Bertschi A; Hayoz D; Gerc V; Brouard R; Lahmy JP; Brunner HR; Burnier M Hypertension; 1997 Nov; 30(5):1121-7. PubMed ID: 9369265 [TBL] [Abstract][Full Text] [Related]
2. Safety, tolerability, and pharmacokinetics of SR 49059, a V1a vasopressin receptor antagonist, after repeated oral administration in healthy volunteers. Brouard R; Laporte V; Serradeil Le Gal C; Pignol R; Jang H; Donat F; Lockwood G; Fournie D; Dreux F Adv Exp Med Biol; 1998; 449():455-65. PubMed ID: 10026839 [TBL] [Abstract][Full Text] [Related]
3. Effects of SR 49059, a non-peptide antagonist of vasopressin V1a receptors, on vasopressin-induced coronary vasoconstriction in conscious rabbits. Serradeil-Le Gal C; Villanova G; Boutin M; Maffrand JP; Le Fur G Fundam Clin Pharmacol; 1995; 9(1):17-24. PubMed ID: 7768483 [TBL] [Abstract][Full Text] [Related]
5. Effects of the vasopressin V1a receptor antagonist, SR 49059, on the response of human uterine arteries to vasopressin and other vasoactive substances. Kostrzewska A; Laudanski T; Steinwall M; Bossmar T; Serradeil-Le Gal C; Akerlund M Acta Obstet Gynecol Scand; 1998 Jan; 77(1):3-7. PubMed ID: 9492709 [TBL] [Abstract][Full Text] [Related]
6. Effects of the nonpeptide V(1) vasopressin receptor antagonist SR49059 in hypertensive patients. Thibonnier M; Kilani A; Rahman M; DiBlasi TP; Warner K; Smith MC; Leenhardt AF; Brouard R Hypertension; 1999 Dec; 34(6):1293-300. PubMed ID: 10601133 [TBL] [Abstract][Full Text] [Related]
7. Effects of OPC-21268, an orally effective vasopressin V1 receptor antagonist in humans. Imaizumi T; Harada S; Hirooka Y; Masaki H; Momohara M; Takeshita A Hypertension; 1992 Jul; 20(1):54-8. PubMed ID: 1319959 [TBL] [Abstract][Full Text] [Related]
8. Vasopressin-induced facilitation of adrenergic responses in the rat mesenteric artery is V1-receptor dependent. Streefkerk JO; Pfaffendorf M; van Zwieten PA Auton Autacoid Pharmacol; 2003 Feb; 23(1):35-41. PubMed ID: 14565536 [TBL] [Abstract][Full Text] [Related]
9. Modulation of the effect of arginine-vasopressin on water and ion transport in the newt early distal tubule and frog urinary bladder by V1-antagonists. Goncharevskaya OA; Shakhmatova EI; Natochin YV Pflugers Arch; 1995 Oct; 430(6):1004-11. PubMed ID: 8594534 [TBL] [Abstract][Full Text] [Related]
10. Enhanced renal vasoconstriction induced by vasopressin in SHR is mediated by V1 receptors. Feng JJ; Arendshorst WJ Am J Physiol; 1996 Aug; 271(2 Pt 2):F304-13. PubMed ID: 8770161 [TBL] [Abstract][Full Text] [Related]
11. Nitric oxide, but not vasopressin V2 receptor-mediated vasodilation, modulates vasopressin-induced renal vasoconstriction in rats. Loichot C; Cazaubon C; De Jong W; Helwig JJ; Nisato D; Imbs JL; Barthelmebs M Naunyn Schmiedebergs Arch Pharmacol; 2000 Mar; 361(3):319-26. PubMed ID: 10731046 [TBL] [Abstract][Full Text] [Related]
12. Potent inhibitory effect of SR 49059, an orally active non-peptide vasopressin VIa receptor antagonist, on human arterial coronary bypass graft. Liu JJ; Chen JR; Buxton BB; Johnston CI; Burrell LM Clin Sci (Lond); 1995 Nov; 89(5):481-5. PubMed ID: 8549062 [TBL] [Abstract][Full Text] [Related]
13. Oxytocin and vasopressin constrict rat isolated uterine resistance arteries by activating vasopressin V1A receptors. Chen YL; Shepherd C; Spinelli W; Lai FM Eur J Pharmacol; 1999 Jul; 376(1-2):45-51. PubMed ID: 10440088 [TBL] [Abstract][Full Text] [Related]
15. Vasopressin-mediated forearm vasodilation in normal humans. Evidence for a vascular vasopressin V2 receptor. Hirsch AT; Dzau VJ; Majzoub JA; Creager MA J Clin Invest; 1989 Aug; 84(2):418-26. PubMed ID: 2527249 [TBL] [Abstract][Full Text] [Related]
16. The influence of intra-arterial infusion of arginine vasopressin on cochlear blood flow in the rat. McLaren GM; Coleman JK; Quirk WS; Dengerink HA; Wright JW Hear Res; 1991 Sep; 55(1):1-8. PubMed ID: 1752789 [TBL] [Abstract][Full Text] [Related]
17. Lack of effect of a selective vasopressin V1A receptor antagonist SR 49,059, on potentiation by vasopressin of adrenoceptor-mediated pressor responses in the rat mesenteric arterial bed. Heinemann A; Horina G; Stauber RE; Pertl C; Holzer P; Peskar BA Br J Pharmacol; 1998 Nov; 125(6):1120-7. PubMed ID: 9863637 [TBL] [Abstract][Full Text] [Related]
18. Effect of the non-peptide, vasopressin V1a receptor antagonist, SR 49059 and its enantiomer, SR 49770, on isolated human myometrium. Bossmar T; Rasmussen T; Akerlund M Acta Obstet Gynecol Scand; 1996 Jul; 75(6):516-9. PubMed ID: 8693925 [TBL] [Abstract][Full Text] [Related]
19. Effect of a new, potent, non-peptide V1a vasopressin antagonist, SR 49059, on the binding and the mitogenic activity of vasopressin on Swiss 3T3 cells. Serradeil-Le Gal C; Bourrié B; Raufaste D; Carayon P; Garcia C; Maffrand JP; Le Fur G; Casellas P Biochem Pharmacol; 1994 Feb; 47(4):633-41. PubMed ID: 8129742 [TBL] [Abstract][Full Text] [Related]
20. Effects of SR 49059, an orally active V1a vasopressin receptor antagonist, on vasopressin-induced uterine contractions. Bossmar T; Brouard R; Döberl A; Akerlund M Br J Obstet Gynaecol; 1997 Apr; 104(4):471-7. PubMed ID: 9141585 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]